JP2017527614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527614A5 JP2017527614A5 JP2017531457A JP2017531457A JP2017527614A5 JP 2017527614 A5 JP2017527614 A5 JP 2017527614A5 JP 2017531457 A JP2017531457 A JP 2017531457A JP 2017531457 A JP2017531457 A JP 2017531457A JP 2017527614 A5 JP2017527614 A5 JP 2017527614A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- pharmaceutical preparation
- subject
- pharmaceutical
- kidney disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022180359A JP2023011921A (ja) | 2014-09-02 | 2022-11-10 | 重水素化又は非重水素化分子及び医薬製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044566P | 2014-09-02 | 2014-09-02 | |
| US62/044,566 | 2014-09-02 | ||
| PCT/US2015/047822 WO2016036674A1 (en) | 2014-09-02 | 2015-08-31 | Deuterated or a non-deuterated molecule and pharmaceutical formulations |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020153867A Division JP2021001193A (ja) | 2014-09-02 | 2020-09-14 | 重水素化又は非重水素化分子及び医薬製剤 |
| JP2022180359A Division JP2023011921A (ja) | 2014-09-02 | 2022-11-10 | 重水素化又は非重水素化分子及び医薬製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527614A JP2017527614A (ja) | 2017-09-21 |
| JP2017527614A5 true JP2017527614A5 (https=) | 2018-10-11 |
Family
ID=55401248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531457A Pending JP2017527614A (ja) | 2014-09-02 | 2015-08-31 | 重水素化又は非重水素化分子及び医薬製剤 |
| JP2020153867A Pending JP2021001193A (ja) | 2014-09-02 | 2020-09-14 | 重水素化又は非重水素化分子及び医薬製剤 |
| JP2022180359A Pending JP2023011921A (ja) | 2014-09-02 | 2022-11-10 | 重水素化又は非重水素化分子及び医薬製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020153867A Pending JP2021001193A (ja) | 2014-09-02 | 2020-09-14 | 重水素化又は非重水素化分子及び医薬製剤 |
| JP2022180359A Pending JP2023011921A (ja) | 2014-09-02 | 2022-11-10 | 重水素化又は非重水素化分子及び医薬製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9375408B2 (https=) |
| EP (2) | EP3628640B1 (https=) |
| JP (3) | JP2017527614A (https=) |
| CN (1) | CN106794986A (https=) |
| AU (4) | AU2015312134A1 (https=) |
| CA (1) | CA2959965A1 (https=) |
| IL (2) | IL285760B2 (https=) |
| MX (2) | MX372723B (https=) |
| WO (1) | WO2016036674A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1888548E (pt) | 2005-05-26 | 2012-10-30 | Neuron Systems Inc | Derivado de quinolina para o tratamento de doenças da retina |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| EP3628640B1 (en) | 2014-09-02 | 2023-08-09 | Hub Therapeutics | Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| WO2017218004A1 (en) * | 2016-06-17 | 2017-12-21 | Michael Hudnall | Medical food for patients with chronic liver disease |
| MX2019010576A (es) | 2017-03-16 | 2019-10-07 | Aldeyra Therapeutics Inc | Compuestos polimorficos y usos de los mismos. |
| US10934241B2 (en) * | 2017-06-16 | 2021-03-02 | University Of North Florida Board Of Trustees | Curcuminoid-inspired synthetic compounds as anti-tumor agents |
| US11117907B2 (en) | 2017-06-16 | 2021-09-14 | University Of North Florida Board Of Trustees | Curcuminoid-inspired synthetic compounds as anti-tumor agents |
| JP7311162B2 (ja) | 2017-10-10 | 2023-07-19 | アルデイラ セラピューティクス， インコーポレイテッド | 炎症性障害の処置 |
| KR20210019459A (ko) * | 2018-05-24 | 2021-02-22 | 레니버스 테라퓨틱스, 인크. | 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법 |
| WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020181256A1 (en) * | 2019-03-06 | 2020-09-10 | Renibus Therapeutics, Inc. | Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CA3142023A1 (en) * | 2019-05-28 | 2020-12-03 | Case Western Reserve University | Compositions and methods for preserving dna methylation |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| CN111017878B (zh) * | 2019-12-18 | 2021-12-17 | 中国原子能科学研究院 | 一种用于制备平衡态h2-hd-d2标准气体的装置和方法 |
| WO2021138561A1 (en) * | 2019-12-31 | 2021-07-08 | Renibus Therapeutics, Inc. | Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same |
| US11883371B2 (en) * | 2020-03-23 | 2024-01-30 | Renibus Therapeutics, Inc. | Stress test and treatment of chronic kidney disease |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
| AU2021281223A1 (en) | 2020-05-27 | 2023-01-05 | Case Western Reserve University | Compositions and methods for preserving DNA methylation |
| CN111759820B (zh) * | 2020-08-24 | 2022-04-19 | 武汉人福药业有限责任公司 | 一种奥卡西平片剂及其制备方法 |
| WO2022203674A1 (en) * | 2021-03-25 | 2022-09-29 | Majeed, Muhammed | Compositions and methods for managing nephropathy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5276182A (en) | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
| DE4039602A1 (de) | 1990-12-12 | 1992-06-17 | Bauer Kurt Heinz Prof Dr | Pharmazeutische formulierungen |
| KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
| US5683676A (en) | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
| ES2224200T3 (es) | 1992-11-27 | 2005-03-01 | Mayne Pharma (Usa) Inc. | Composicion inyectable estable de paclitaxel. |
| US5654286A (en) | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| CZ301771B6 (cs) | 1993-10-01 | 2010-06-16 | Syntex (U.S.A.) Llc. | Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5653987A (en) | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| US6342507B1 (en) * | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| JPH11246398A (ja) * | 1998-03-02 | 1999-09-14 | Kyowa Hakko Kogyo Co Ltd | 生体内過酸化脂質増加に起因する疾患の予防または治療剤 |
| US7442720B2 (en) * | 2003-12-19 | 2008-10-28 | Omega Bio-Pharma (I.P.3) Limited | Compositions and methods for treating diabetes |
| NZ548195A (en) * | 2004-01-14 | 2011-01-28 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
| US8841326B2 (en) * | 2004-02-12 | 2014-09-23 | Stc.Unm | Therapeutic curcumin derivatives |
| CN1283237C (zh) | 2004-11-22 | 2006-11-08 | 山东大学 | 姜黄素磷脂复合物及其制备方法 |
| US7776915B2 (en) | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| AU2006274037B2 (en) * | 2005-07-26 | 2012-04-26 | Takeda Gmbh | Isotopically substituted pantoprazole |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| JP2007320864A (ja) * | 2006-05-30 | 2007-12-13 | Toshihiko Osawa | 非アルコール性脂肪肝炎予防・治療用組成物 |
| JP2008133272A (ja) * | 2006-10-31 | 2008-06-12 | Ito En Ltd | Ｃｐｔ活性亢進剤及び飲食物 |
| JP2008201768A (ja) * | 2006-11-24 | 2008-09-04 | Mizu Kk | 抗炎症剤及びシクロオキシゲナーゼ阻害剤 |
| WO2008093848A1 (ja) * | 2007-02-02 | 2008-08-07 | Sunstar Inc. | ホスファチジルコリンを含有する炎症マーカー低減組成物 |
| WO2010097643A1 (en) * | 2009-02-24 | 2010-09-02 | Novatech Istrazivanje D.O.O. | Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite |
| JP5416472B2 (ja) * | 2009-05-07 | 2014-02-12 | 株式会社セラバリューズ | ウコン色素組成物による心機能改善効果 |
| CN101627969B (zh) * | 2009-07-30 | 2011-06-29 | 浙江工业大学 | 一种姜黄素自乳化给药系统及其制备 |
| WO2011047309A2 (en) * | 2009-10-16 | 2011-04-21 | The Research Foundation Of State University Of New York | Treatment of ischemic tissue |
| CN102526003B (zh) * | 2010-01-25 | 2014-02-19 | 四川省中医药科学院 | 四氢姜黄素的用途 |
| CN101732292B (zh) * | 2010-01-25 | 2012-05-16 | 四川省中医药科学院 | 四氢姜黄素的用途 |
| WO2011116066A1 (en) * | 2010-03-17 | 2011-09-22 | Concert Pharmaceuticals, Inc. | Derivatives of dimethylcurcumin |
| WO2013033250A1 (en) * | 2011-09-01 | 2013-03-07 | Xiangping Qian | Certain chemical entities, compositions, and methods |
| CN104739813A (zh) * | 2013-12-26 | 2015-07-01 | 四川省中医药科学院 | 四氢姜黄素的新用途 |
| EP3628640B1 (en) * | 2014-09-02 | 2023-08-09 | Hub Therapeutics | Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment |
-
2015
- 2015-08-31 EP EP19200739.1A patent/EP3628640B1/en active Active
- 2015-08-31 JP JP2017531457A patent/JP2017527614A/ja active Pending
- 2015-08-31 WO PCT/US2015/047822 patent/WO2016036674A1/en not_active Ceased
- 2015-08-31 EP EP15838029.5A patent/EP3189007B1/en active Active
- 2015-08-31 CA CA2959965A patent/CA2959965A1/en active Pending
- 2015-08-31 AU AU2015312134A patent/AU2015312134A1/en not_active Abandoned
- 2015-08-31 CN CN201580055310.6A patent/CN106794986A/zh active Pending
- 2015-08-31 IL IL285760A patent/IL285760B2/en unknown
- 2015-08-31 MX MX2017002750A patent/MX372723B/es active IP Right Grant
- 2015-08-31 US US14/841,229 patent/US9375408B2/en active Active
-
2016
- 2016-06-23 US US15/190,689 patent/US10781158B2/en active Active
-
2017
- 2017-03-01 IL IL250861A patent/IL250861B/en unknown
- 2017-03-01 MX MX2020005446A patent/MX2020005446A/es unknown
-
2019
- 2019-10-14 AU AU2019250097A patent/AU2019250097A1/en not_active Abandoned
-
2020
- 2020-08-19 US US16/997,255 patent/US20200377441A1/en not_active Abandoned
- 2020-09-14 JP JP2020153867A patent/JP2021001193A/ja active Pending
-
2021
- 2021-09-22 AU AU2021236495A patent/AU2021236495A1/en not_active Abandoned
-
2022
- 2022-11-10 JP JP2022180359A patent/JP2023011921A/ja active Pending
-
2023
- 2023-11-27 AU AU2023274063A patent/AU2023274063A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527614A5 (https=) | ||
| Amin et al. | Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension | |
| JP2015503593A5 (https=) | ||
| JP2011516613A5 (https=) | ||
| DeFronzo et al. | Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes | |
| JP2015522029A5 (https=) | ||
| JP2014533680A5 (https=) | ||
| Amle et al. | Bioactive herbal medicine use for eye sight: a meta analysis | |
| HRP20131120T1 (hr) | Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa | |
| KR20100094981A (ko) | 간염치료용 실리비닌 성분 | |
| Li et al. | Antidiabetic activity of lipophilic (−)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition | |
| JP2021534105A5 (https=) | ||
| Jia-Yi et al. | Effect and mechanism of Qishen Yiqi Pills on adriamycin-induced cardiomyopathy in mice | |
| JP2014533701A5 (https=) | ||
| Noor et al. | Curcuminoids as cell signaling pathway modulators: a potential strategy for cancer prevention | |
| Cao et al. | Sarcandra glabra extract reduces the susceptibility and severity of influenza in restraint‐stressed mice | |
| Javed et al. | Functional Food Industry | |
| WO2017220050A3 (zh) | 阿奇霉素的药物组合物及其止咳的医药用途 | |
| JP2018529763A5 (https=) | ||
| Lancet | Prediabetes and the potential to prevent diabetes | |
| CN111228248A (zh) | 一种治疗肝损伤的药物及花姜酮在制备治疗肝损伤药物方面的应用 | |
| Kochhar et al. | Yogic Diet and its Anti-inflammatory Effect in Relation to CVD | |
| CN104983727A (zh) | 鱼藤酮在制备降低肝脏脂肪沉积药物中的应用 | |
| JPWO2020030612A5 (https=) | ||
| Kavadi | Role of Sotagliflozin in Managing Heart Failure in Diabetes |